Urticaria may be acute or chronic. As opposed to acute urticaria, chronic urticaria is defined by recurrent episodes occurring at least twice a week for 6 weeks (Grattan, Sabroe, & Greaves ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Treatment is difficult, involving fluid replacement and C1 esterase inhibitor concentrate for acute attacks (not approved in the U.S.) and prophylactic treatment with anabolic androgens and ...

The international urticaria guideline reflects worldwide ... may be considered in patients with an acute exacerbation. Treatment step-down and assessment of spontaneous remission is recommended ...

Acute urticaria is often caused by allergic ... tests may be performed to identify specific triggers. The goal of urticaria treatment is to alleviate symptoms and, if possible, address the root ...

Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxis ALK also gains rights to future indications, including acute urticaria flares (in ...

Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, Evommune, and others are evaluating new urticaria drugs to improve the treatment landscape. Promising pipeline urticaria ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

DelveInsight’s 'Urticaria Pipeline Insight 2024' report provides comprehensive global coverage of pipeline urticaria therapies in various stages of clinical development, major pharmaceutical companies ...

to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target ...